Get the Stockscreener App
2.62
1.87%
-0.05
Immunitybio Inc stock is traded at $2.62, with a volume of 7.82M.
It is down -1.87% in the last 24 hours and down -46.26% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
See More
Previous Close:
$2.67
Open:
$2.66
24h Volume:
7.82M
Relative Volume:
1.30
Market Cap:
$1.91B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.2982
EPS:
-1.14
Net Cash Flow:
$-425.62M
1W Performance:
-8.71%
1M Performance:
-46.26%
6M Performance:
-59.69%
1Y Performance:
-42.16%
1-Day Range:
$2.61
$2.7065
1-Week Range:
$2.61
$3.18
52-Week Range:
$2.61
$10.53
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.62 | 1.91B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Sets New 1-Year LowShould You Sell? - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6%Here's Why - MarketBeat
ImmunityBio: Forging A New Plan After Recent $100 Million Offering - Seeking Alpha
ImmunityBio Shares Plunge After Share Offering - Los Angeles Business Journal
ImmunityBio (NASDAQ:IBRX) Hits New 52-Week LowShould You Sell? - MarketBeat
ImmunityBio: Despite Share Price & Funding Woes Muddy Path To Long-Term Success (IBRX) - Seeking Alpha
ImmunityBio stock plummets on announcing common stock offering - MSN
D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering - Yahoo Finance
Form 424B5 ImmunityBio, Inc. - StreetInsider.com
SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow
ImmunityBio announces proposed public offering of common stock - MSN
ImmunityBio’s Cash Burn And Dilution Dampen Anktiva’s Potential (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Shares Slide 33% After Public Offering Prices - MarketWatch
What's Going On With ImmunityBio Shares Wednesday? - Benzinga
IMMUNITYBIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc.IBRX - The Eastern Progress Online
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock - Business Wire
ImmunityBio Shares Down on Plans for Public Offering - MarketWatch
ImmunityBio plans public stock offering By Investing.com - Investing.com Canada
ImmunityBio plans public stock offering - Investing.com India
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock - Business Wire
Biotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock Move - MSN
More layoffs for ImmunityBio's Dunkirk facility - MSN
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment - The Eastern Progress Online
(IBRX) Investment Analysis - Stock Traders Daily
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
ImmunityBio and nCartes partner to automate clinical trial data processes - Clinical Trials Arena
Town hopeful after ImmunityBio tour - Evening Observer
Town Hopeful After ImmunityBio Tour - Jamestown Post Journal
ImmunityBio partners with nCartes to streamline trials - Investing.com
ImmunityBio and nCartes Enter Collaboration Agreement on Clinica - GuruFocus.com
ImmunityBio, nCartes announce collaboration on clinical trial data fulfillment - TipRanks
ImmunityBio partners with nCartes to streamline trials By Investing.com - Investing.com UK
ImmunityBio Partners with nCartes to Revolutionize Clinical Trial Data Management | IBRX Stock News - StockTitan
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet - MSN
Immunitybio Inc earnings beat by $0.04, revenue topped estimates - Investing.com Nigeria
ImmunityBio (IBRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months - BioSpace
ImmunityBio announces new data from QUILT 3.032 study - TipRanks
ImmunityBio's Bladder Cancer Drug Shows 71% Response Rate in Key Trial | IBRX Stock News - StockTitan
Following recent decline, ImmunityBio, Inc.'s (NASDAQ:IBRX) top shareholder Chief Scientific Officer Patrick Soon-Shiong sees holdings value drop by 11% - Simply Wall St
ImmunityBio Inc. Reports Earnings Amid Financial Challenges - TipRanks
ImmunityBio Inc (IBRX) Q3 2024 Earnings: GAAP EPS of -$0.12, Rev - GuruFocus.com
ImmunityBio: Q3 Earnings Snapshot - The Pioneer
ImmunityBio Inc. (IBRX) Quarterly 10-Q Report - Quartzy
Innovative Bladder Cancer Therapy Produces $6 Million in Sales - Precision Vaccinations
ImmunityBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adcock Richard | CEO & President |
Feb 05 '24 |
Option Exercise |
0.00 |
83,334 |
0 |
286,303 |
| Simon Barry J. | Director |
Jan 31 '24 |
Option Exercise |
0.00 |
57,200 |
0 |
3,145,855 |
| Sachs David C. | Chief Financial Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
70,745 |
0 |
212,673 |
| LAUER REGAN J | Chief Accounting Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
32,872 |
0 |
107,804 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '23 |
Option Exercise |
0.00 |
30,397 |
0 |
152,439 |
| Adcock Richard | CEO & President |
Dec 31 '23 |
Option Exercise |
0.00 |
34,483 |
0 |
220,065 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):